aSamples collected after the last cancer treatment (either systemic or local) will be considered as fresh biopsies. Abbreviations: AE = adverse event; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransfer ase; BUN = blood ur ea nit rogen; C1 = Cycle 1; CA19-9 = cancer antigen 19-9; CBC = complete blood count; CEA = cancer embryonic antigen; CrCl = creatinin e clearance; CRF = Case Report Form; CRP = C-reactive protein; D1 = Day 1; ECOG = Eastern Cooperative Oncology Group; eS AE = electronic serious adverse event; FFPE = formalin-fixed paraffin-embedded; GGT = g amma-glutamyl transferase; HIV = human immunodeficiency virus; ICOS = Inducible T-cell COStimulator; IRT = Interactive Response Technology; LDH = lactate dehydrogenase; NSCLC = non-small-cell lung canc er; PD-L1 = programmed death ligand 1; PSA = prostate-specific antigen; RNA = ribonucleic acid; SAE = serious adverse event; T3 = trii odothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; WOCBP = women of childbearing potential. Revised Protocol No.: 04 Date: 31-May-2019 22 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-2: On-treatment Procedural Outline (CA021002) Procedures for Safety Cohort, and Parts A, B, C, D and Ea,bC1C2 to beyondC2 OnlyC2 OnlyNotes Procedure D1 D2D8 ±±1 daysD15 ±1 daysD22 ±1 daysD1 D2D8 ±1 daysEOT c,d,e Safety Assessments Full PE X X Pre-dose (Cycle 1 Only) Symptom-directed PE X X X X X To include signs and symptoms Physical measurements X XIncludes weight only.